• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3.
【24h】

Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3.

机译：低剂量普伐他汀对日本II型载脂蛋白E表型E3 / 2，E3 / 3和E4 / 3的高脂蛋白血症受试者的血脂和载脂蛋白水平的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Effects of 12 weeks of treatment with pravastatin at a dose of 20 mg/day were compared in subjects with type II hyperlipoproteinemia with apo+(lipoprotein) E phenotype E3/2, E3/3, and E4/3. There were no differences in age, body mass index, smoking status, complications, or plasma levels of lipids and apoproteins, except the higher levels of apo E in E3/2 subjects (n = 11) than in E3/3 subjects (n = 84) and E4/3 subjects (n = 28). Plasma levels of low-density lipoprotein cholesterol (LDL-C) were reduced by 47% +/- 8% (mean +/- SD) in E3/2 subjects, 36% +/- 10% in E3/3 subjects, and 26% +/- 12% in E4/3 subjects after 12 weeks of treatment with pravastatin (all p < 0.0001). Plasma levels of apo B were decreased by 40% +/- 12% in E3/2 subjects, 27% +/- 10% in E3/3 subjects, and 18% +/- 14% in E4/3 subjects after 12 weeks of treatment with pravastatin (all p < 0.0001). The reduction in plasma levels of LDL-C and apo B was most marked in E3/2 subjects, next in E3/3 subjects, and smallest in E4/3 subjects. The authors conclude that treatment with pravastatin at a dose of 20 mg/day in Japanese subjects is equally effective as 40 mg/day in Western subjects, and apo Epolymorphism is a factor to determine the efficacy of pravastatin in Japanese subjects.
机译：在患有apo +（脂蛋白）E表型E3 / 2，E3 / 3和E4 / 3的II型高脂蛋白血症的受试者中比较了普伐他汀以20 mg /天的剂量治疗12周的效果。除E3 / 2受试者（n = 11）的Epo E水平高于E3 / 3受试者（n = 11）外，年龄，体重指数，吸烟状况，并发症或血浆脂质和载脂蛋白水平无差异。 84）和E4 / 3主题（n = 28）。 E3 / 2受试者的低密度脂蛋白胆固醇（LDL-C）血浆水平降低了47％+/- 8％（平均+/- SD），E3 / 3受试者的血浆水平降低了36％+/- 10％，并且普伐他汀治疗12周后，在E4 / 3受试者中为26％+/- 12％（所有p <0.0001）。在12周后，E3 / 2受试者的apo B血浆水平降低了40％+/- 12％，E3 / 3受试者降低了27％+/- 10％，E4 / 3受试者降低了18％+/- 14％普伐他汀治疗（所有p <0.0001）。 LDL-C和载脂蛋白B的血浆水平降低在E3 / 2受试者中最为明显，在E3 / 3受试者中次之，在E4 / 3受试者中最小。作者得出的结论是，在日本受试者中以20 mg /天的剂量使用普伐他汀治疗与在西方受试者中40 mg /天的治疗效果相同，并且载脂蛋白多态性是决定普伐他汀在日本受试者中疗效的因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号